Biofilm, Morbidity, Ureteral Catheterization
Conditions
Brief summary
This study is performed to analyze various aspects of biofilms on ureteral stents.
Detailed description
The study is performed to provide a better understanding of the influence of biofilms on ureteral stents on the entire spectrum of stent-associated morbidity. Moreover, it could provide more detailed knowledge about the correlation of the occurrence of biofilms on ureteral stents and findings in urinary analysis, which could serve as a decision support whether patients with ureteral stents undergoing further interventions (for example ESWL or simple secondary URS) should receive antibiotic prophylaxis. Correlation of results of urinary bacteriologies (assessed pre- and intraoperatively) and biofilm analysis on stents could provide information if targeted antibiotic treatment based on urinary bacteriology only is possible at all. Correlation of urinary analysis and conventional urinary bacteriology could provide a valuable contribution regarding the prediction of bacteriuria and the necessity of postponing operations. Additionally, the study is intended to provide an overview over the recent bacterial species that are involved into biofilms on ureteral stents and their resistance to antibiotics. This could provide valuable information about the choice of antibiotics in cases were treatment has to be performed empirically.
Interventions
Sponsors
Cantonal Hospital of St. Gallen
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients temporarily undergoing ureteral stenting * Informed consent
Exclusion criteria
* Bilateral stenting * Ureteral obstruction due to malignancies * Additionally performed procedures/operations during stent indwelling time -Cognitively impaired patients * UTI at the time of stent insertion (\>10 to the power of 2 cfu/ml)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total biofilm mass on ureteral stents. | Time of stent removal: Four weeks (range 2-6 weeks) after stent insertion |
| Assessment of morbidity using the Ureteral Stent Symptom Questionnaire (USSQ) | Day before stent removal (i.e. 4 weeks (range 2-6 weeks) after insertion) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Urine Culture | Before study inclusion; Day before stent removal (i.e. 4 weeks (range 2-6 weeks) after insertion); Intraoperatively (during stent removal) | — |
| Rapid immunoassay test for bacteriuria | Day before stent removal (i.e. 4 weeks (range 2-6 weeks) after insertion) | — |
| Assessment of morbidity using the Ureteral Stent Symptom Questionnaire (USSQ) | One week after stent insertion; Four weeks (range 2-6 weeks) after stent removal. | — |
| Number of bacteria on stent surface (cell count as estimated by scanning electron microscopy) | Day of stent removal: Four weeks (range 2-6 weeks) after stent insertion | — |
| Number of bacteria on stent surface (determined via quantitative PCR) | Day of stent removal: Four weeks (range 2-6 weeks) after stent insertion | — |
| Next generation sequencing of biofilms | Day of stent removal: Four weeks (range 2-6 weeks) after stent insertion | To identify bacterial species that are involved into biofilms on ureteral stents. |
| Urinary analysis (pH, nitrite, leucocyturia, hematuria). | Day before stent removal (i.e. 4 weeks (range 2-6 weeks) after insertion) | — |
Countries
Switzerland
Outcome results
None listed